Open AccessReduced Albuminuria with Sarpogrelate Is Accompanied by a Decrease in Monocyte Chemoattractant Protein-1 Levels in Type 2 Diabetes
Author(s) -
Susumu Ogawa,
Takefumi Mori,
Kazuhiro Nako,
Tsuneo Ishizuka,
Sadayoshi Ito
Publication year - 2008
Publication title -
clinical journal of the american society of nephrology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.755
H-Index - 151
eISSN - 1555-905X
pISSN - 1555-9041
DOI - 10.2215/cjn.03450807
Subject(s) - medicine , albuminuria , monocyte , type 2 diabetes , diabetes mellitus , endocrinology
Sarpogrelate has been shown to reduce albuminuria in diabetic nephropathy. For examination of whether this is based on the same mechanisms as angiotensin II receptor blockers or thiazolidinedione, effects of sarpogrelate on atherosclerotic inflammatory molecules and their relations to albuminuria in patients who had diabetes and had already been treated with angiotensin II receptor blockers and with or without thiazolidinedione were examined.